Australian Biobest Biotechnology Service

Belkins
Australian Biobest Biotechnology Service (Biobest) is formed with a group of biotech specialists with expertise on lab bench-top biotechnology transfer to market places, biological product (especially on humanised monoclonal antibody and biosimilar) manufacturing experiences, biopharmaceutical and biological reagent marketing, licencing and registration, biomedical instrument (Biacore, Cytometer) services, scientific conference and training services, biotechnological project management and documentation and website design and biotech documentation translation.

Related News

AI

EUREKARE AND DNALYTICS FORM PARTNERSHIP TO DEVELOP A PROPRIETARY AI PLATFORM

eureKARE | July 07, 2021

news image

eureKARE, a pioneering new company focused on financing and building next-generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology, today announced an agreement with DNAlytics, a Belgian company applying data sciences to healthcare, to develop eureKARE's proprietary Artificial Intelligence (AI) platform to support its Biotech start-upstart-up studios, eureKARE. Unlike conventional start-upstart-up incubation methods, which begin with ...

Read More

INNATOSS LABORATORIES LAUNCHES NEUTRALIZING ANTIBODY TESTING SERVICE AGAINST SARS-COV-2 USING GENSCRIPT'S CPASS ™ KIT

Innatoss Laboratories | September 15, 2020

news image

Innatoss Laboratories announced today the first neutralizing antibody testing service against SARS-CoV-2 for the public in Europe, using GenScript's cPass ™ SARS-CoV-2 Neutralization Antibody Detection Kit. The kit is the first in the world that enables rapid detection of neutralizing antibodies (NAbs), the specific antibodies present in the serum of COVID-19 patients that are responsible for clearing the viral infection. Innatoss is the first medical lab in Europe to provide a service...

Read More

SAMSUNG BIOLOGICS, VIR BIOTECHNOLOGY TEAM UP TO FIGHT COVID-19

BioSpectrum Asia | April 13, 2020

news image

South Korea based Samsung Biologics and US based Vir Biotechnology, Inc. have announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services Vir's SARS-CoV-2 monoclonal antibody (mAb) program. Vir's lead SRS-CoV-2 mAb development candidates, VIR-7831 and VIR-7832, have demonstrated high affinity for the SARS-CoV-2 spike protein and are highly potent in neutralizing SARS-CoV-2 in live-virus cellular assays. Vir plans to proceed directly i...

Read More

CARDIFF ONCOLOGY ANNOUNCES $2.5 MILLION EQUITY INVESTMENT BY BIOTECH-FOCUSED FUNDAMENTAL INVESTOR ACORN BIOVENTURES

Cardiff Oncology | May 27, 2020

news image

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant prostate cancer and leukemia, today announced it has entered into a definitive securities purchase agreement with biotech-focused fundamental investor, Acorn Bioventures, LP, for $2.5 million.Under the agreement, Acorn Bioventures has agreed to purchas...

Read More

AI

eureKARE | July 07, 2021

news image

EUREKARE AND DNALYTICS FORM PARTNERSHIP TO DEVELOP A PROPRIETARY AI PLATFORM

eureKARE, a pioneering new company focused on financing and building next-generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology, today announced an agreement with DNAlytics, a Belgian company applying data sciences to healthcare, to develop eureKARE's proprietary Artificial Intelligence (AI) platform to support its Biotech start-upstart-up studios, eureKARE. Unlike conventional start-upstart-up incubation methods, which begin with ...

Read More

Innatoss Laboratories | September 15, 2020

news image

INNATOSS LABORATORIES LAUNCHES NEUTRALIZING ANTIBODY TESTING SERVICE AGAINST SARS-COV-2 USING GENSCRIPT'S CPASS ™ KIT

Innatoss Laboratories announced today the first neutralizing antibody testing service against SARS-CoV-2 for the public in Europe, using GenScript's cPass ™ SARS-CoV-2 Neutralization Antibody Detection Kit. The kit is the first in the world that enables rapid detection of neutralizing antibodies (NAbs), the specific antibodies present in the serum of COVID-19 patients that are responsible for clearing the viral infection. Innatoss is the first medical lab in Europe to provide a service...

Read More

BioSpectrum Asia | April 13, 2020

news image

SAMSUNG BIOLOGICS, VIR BIOTECHNOLOGY TEAM UP TO FIGHT COVID-19

South Korea based Samsung Biologics and US based Vir Biotechnology, Inc. have announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services Vir's SARS-CoV-2 monoclonal antibody (mAb) program. Vir's lead SRS-CoV-2 mAb development candidates, VIR-7831 and VIR-7832, have demonstrated high affinity for the SARS-CoV-2 spike protein and are highly potent in neutralizing SARS-CoV-2 in live-virus cellular assays. Vir plans to proceed directly i...

Read More

Cardiff Oncology | May 27, 2020

news image

CARDIFF ONCOLOGY ANNOUNCES $2.5 MILLION EQUITY INVESTMENT BY BIOTECH-FOCUSED FUNDAMENTAL INVESTOR ACORN BIOVENTURES

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant prostate cancer and leukemia, today announced it has entered into a definitive securities purchase agreement with biotech-focused fundamental investor, Acorn Bioventures, LP, for $2.5 million.Under the agreement, Acorn Bioventures has agreed to purchas...

Read More